Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Why Is This Generic Manufacturer Being Trampled by Its Industry Rivals? | The Motley Fool
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Mylan vs Teva Pharmaceuticals | Comparably
FDA Approves Teva's Generic EpiPen As Stock Rises
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva Projects Generic Version of EpiPen to Consist of a Quarter of US Market | The Jewish Press - JewishPress.com | Jewish News Syndicate (JNS) | 16 Adar I 5779 – February 21, 2019 | JewishPress.com
The Teva vs. Mylan drug war - The Jerusalem Post
Lawmakers accuse drugmakers Mylan, Teva of 'coordinated obstruction'
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan - TheStreet
How Mylan tried to keep Teva from selling a generic EpiPen
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
Teva settles litigation with Mylan over Nuvigil - Pharmaceutical Technology
Mylan vs. Teva: Which Is the Better Generics Stock Ahead of Earnings?
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Teva scrambles to match 30% Copaxone discounts from Mylan's knockoff: analyst | Fierce Pharma
Drugmaker Teva makes $40B bid for rival Mylan
Teva makes $40 billion offer for Mylan
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva Offers to Buy Mylan for $40 Billion - WSJ
Tamoxifen Detective: How I got my Teva back | The small c
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva makes $40.1 billion takeover bid for Mylan | Mint
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
